Literature DB >> 35411457

Predicting early discharge and readmission following pancreaticoduodenectomy [S079].

Diana S Hsu1,2, Hyunjee V Kwak3,4, Sidney T Le3,4, George Kazantsev4, Alex L Chang4, Austin L Spitzer4, Peter D Peng4, Ching-Kuo Chang4.   

Abstract

INTRODUCTION: Implementing enhanced recovery after surgery (ERAS) protocols for major abdominal surgery has been shown to decrease length of stay (LOS) and postoperative complications, including mortality and readmission. Little is known to guide which patients undergoing pancreaticoduodenectomy (PD) should be eligible for ERAS protocols. METHODS AND PROCEDURES: A retrospective chart review of all PD performed from 2010 to 2018 within an integrated healthcare system was conducted. A predictive score that ranges from 0 to 4 was developed, with one point assigned to each of the following: obesity (BMI > 30), operating time > 400 min, estimated blood loss (EBL) > 400 mL, low- or high-risk pancreatic remnant (based on the presence of soft gland or small duct). Chi-squared tests and ANOVA were used to assess the relationship between this score and LOS, discharge before postoperative day 7, readmission, mortality, delayed gastric emptying (DGE), and pancreatic leak/fistula.
RESULTS: 291 patients were identified. Mean length of stay was 8.5 days in those patients who scored 0 compared to 16.2 days for those who scored 4 (p = 0.001). 30% of patients who scored 0 were discharged before postoperative day 7 compared to 0% of those who scored 4 (p = 0.019). Readmission rates for patients who scored 0 and 4 were 12% and 33%, respectively (p = 0.017). Similarly, postoperative pancreatic fistula occurred in 2% versus 25% in these groups (p = 0.007).
CONCLUSION: A simple scoring system using BMI, operating time, EBL, and pancreatic remnant quality can help risk-stratify postoperative PD patients. Those with lower scores could potentially be managed via an ERAS protocol. Patients with higher scores required longer hospitalizations, and adjunctive therapy such as medication and surgical technique to decrease risk of delayed gastric emptying and pancreatic fistula could be considered.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  ERAS; ERAS eligibility; ERAS feasibility; Early discharge; Pancreaticoduodenectomy; Readmission

Year:  2022        PMID: 35411457     DOI: 10.1007/s00464-022-09207-9

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  2 in total

1.  Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy.

Authors:  Katherine S Cools; Hanna K Sanoff; Hong Jin Kim; Jen Jen Yeh; Karyn B Stitzenberg
Journal:  J Surg Oncol       Date:  2018-08-16       Impact factor: 3.454

2.  The Safety and Feasibility of Enhanced Recovery after Surgery in Patients Undergoing Pancreaticoduodenectomy: An Updated Meta-Analysis.

Authors:  You-Meng Sun; Ying Wang; Yi-Xin Mao; Wei Wang
Journal:  Biomed Res Int       Date:  2020-05-08       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.